Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

@article{Lacouture2010SkinTE,
  title={Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.},
  author={Mario E. Lacouture and Edith P. Mitchell and Bilal Piperdi and Madhavan V. Pillai and Heather Shearer and Nicholas O. Iannotti and Feng Xu and Mohamed Yassine},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 8},
  pages={
          1351-7
        }
}
  • M. Lacouture, E. Mitchell, +5 authors M. Yassine
  • Published 10 March 2010
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in the United States and Europe for the treatment of refractory metastatic colorectal cancer (mCRC. [...] Key Method Pre-emptive treatment included use of skin moisturizers, sunscreen, topical steroid, and doxycycline. The primary end point of the study was the incidence of protocol-specified >or= grade 2 skin toxicities during the 6-week skin treatment period.Expand
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
TLDR
Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients.
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
TLDR
Panitumumab in combination with irinotecan-based chemotherapy has an acceptable toxicity profile in second-line therapy for mCRC and is effective in patients with wild-type KRAS tumors.
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study
TLDR
A reduction of severe skin toxicities is shown with an increase of grade 1 toxicities, not leading to anti-EGFR dose reduction and with better quality of life for patients.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
TLDR
Although recommended by international guidelines, the pre-emptive approach of anti-EGFR-related skin toxicity in mCRC patients still appears less adopted in daily clinical practice, compared to the reactive one.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
TLDR
A post hoc analysis of the Valentino study that randomized RAS wild-type mCRC patients to two panitumumab-based maintenance regimens after the first-line induction aimed at assessing the safety and efficacy of a pre-emptive doxycycline prophylaxis for anti-EGFR-related skin toxicity.
AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
TLDR
Ierythromycin cannot be regarded as an alternative to doxycycline as prevention of EGFR-related skin toxicity and overall quality of life was comparable between both arms.
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
  • B. Melosky, H. Anderson, +11 authors J. Laskin
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
Prophylactic minocycline and reactive treatment are both acceptable options for the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic NSCLC.
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
TLDR
First-line panitumumab plus FOLFIRI has acceptable tolerability and appears to have little impact on quality of life, despite the high incidence of integument-related toxicity.
Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
TLDR
The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen, demonstrating the benefit of prophylactic treatment for skin toxicity.
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study).
TLDR
In conclusion, panitumumab and irinotecan as salvage therapy for mCRC KRAS wild-type patients with skin toxicity prevention exhibits limited efficacy, and the effect of low-dose irinOTecan with panitUMumab appears to be clinically insignificant.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
TLDR
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated.
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
  • J. Hecht, E. Mitchell, +10 authors R. Amado
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS, and these combinations are not recommended for the treatment of mCRC in clinical practice.
Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results
TLDR
The survey results support that attentive cutaneous care is important in patients treated with EGFR inhibitors, and that proactive/combined interventions may enhance quality of life and optimize consistent drug administration.
Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB)
TLDR
This double- blinded, placebo-controlled trial was conducted to assess the role of tetracycline in preventing EGFR inhibitor-induced rash and/or reducing its severity.
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
TLDR
Physicians and patients should view rash development as a positive event indicative of greater likelihood of clinical benefit and further studies are required to identify patients most likely to develop rash and to determine if dose escalation to induce rash can improve efficacy.
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies
  • S. Segaert, J. Tabernero, +9 authors A. Layton
  • Medicine
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2005
TLDR
An overview of the treatment options for skin reactions that are available today are presented, and some of the ways in which the treatment of such EGFR‐inhibitor‐related skin reactions may be improved in the future are evaluated.
Cetuximab for the treatment of colorectal cancer.
TLDR
Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed.
Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
TLDR
The findings support the concept that p27Kip1 plays a part in the in vivo regulation of follicular and epidermal homeostasis by EGFR.
Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer
TLDR
Novel targeted agents increase the therapeutic armamentarium in metastatic colorectal cancer (mCRC) and tyrosine kinase inhibitors of EGFR seem less effective than their monoclonal antibody counterparts in the therapy of mCRC.
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
  • A. Scope, A. L. Agero, +5 authors A. Halpern
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Prophylaxis with oral minocycline may be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treatment.
...
1
2
3
4
...